Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...
More »SEARCH RESULT
Total Matching Records found : 232
Free medicines as a mission
-The Hindu The Centre's move to introduce an experimental universal health package in at least one district per State under the National Rural Health Mission, with access to free generic drugs, is a welcome measure. But the larger mission to provide free essential medicines to all citizens need not await the results of such pilot studies. It should be rolled out for poor and non-poor alike quickly. There is no time...
More »Cheap generics no panacea for India's poorest
-Reuters Cheap generic drugs were meant to change the life of Nandakhu Nissar, whose mouth is swollen by a cancerous tumour. But the cashless and hungry 55-year-old sleeps on a pavement staring up at the windows of Mumbai's biggest cancer hospital. "What is a generic drug?" shrugs Nissar, who has travelled over 1,500 kms (900 miles) from his home in the hope of treatment. "I have borrowed money from friends and relatives...
More »A historic move to make drugs affordable-G Ananthakrishnan
India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »India's patent ruling on cancer may open door for cheaper HIV drugs
-Reuters India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug...
More »
